Lovastatin enhances in vitro radiation-induced apoptosis of rat B-cell lymphoma cells

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 1, 2005, Pages 55-61

  Rozados, V R ^a   Hinrichsen, L I ^a,b   McDonnell, J ^c   Scharovsky, O Graciela ^a,b  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^c Cumbres SA   (Argentina)

Author keywords

Antitumor effect; Apoptosis; Lovastatin; Lymphoma; Radioresistance

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IN VITRO STUDY; LYMPHOMA CELL; MALE; METASTASIS INHIBITION; MITOSIS INHIBITION; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION; RADIOSENSITIVITY; RADIOSENSITIZATION; RAT; SARCOMA;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; FEMALE; LOVASTATIN; MALE; RATS; TUMOR CELLS, CULTURED;

EID: 18544365784     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. 1 phase blocks. Cell Growth Differ. 4:421-430, 1993.
2. 1 to multiple cell cycles by Lovastatin. Cancer Res. 51:3602-3609, 1991.
3. Goldstein J.L., Brown M.S.: Regulation of the mevalonate pathway. Nature (Lond.) 343:425-430, 1990.
4. Perez-Sala D., Mollinedo F.: Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem. Biophys. Res. Commun. 199:1209-1215, 1994.
5. Quesney-Hueneeus V., Wiley M.H., Siperstein M.D.: Essential role for mevalonate synthesis in DNA replication. Proc. Natl. Acad. Sci. USA 76:5056-5060, 1979.
6. Harwood H.J., Alvarez I.M., Noyes W.D., Stacpoole P.W.: In vivo regulation of human leucocyte-3-hydroxy-3-methylgutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. J. Lipid Res. 32:1327-1352, 1992.
7. Kawata S., Takaishi K., Nagase T. et al.: Increase in the active form of 3-hydroxy-3-methylgutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res. 50:3270-3273, 1990.
8. Feingold K.R., Wiley M.H., Moser A.H., Siperstein M.D.: Altered activation state of 3-hydroxy-3-methylgutaryl coenzyme A reductase in liver tumors. Arch. Biochem. Biophys. 226:231-241, 1983.
9. Maltese W.A., Defendini R., Green R.A., Sheridan K.M., Donley D.K.: Suppression of murine neuroblastoma growth in vivo by mevilonin a competitive inhibitor of 3-hydroxy-3-methylgutaryl CoA reductase. J. Clin. Invest. 76:1748-1754, 1985.
10. Tobert J.A.: Efficacy and long-term adverse effect pattern for Lovastatin. Am. J. Cardiol. 62:28J-34J, 1988.
11. Carlberg M., Drieu A., Blegen H. et al.: Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxi-3-methylglutaryl-coenzyme A reductase and cell growth. J. Biol. Chem. 271:17453-17462, 1996.
12. Castellano F., Bruscalupi G., Columba S., Di-Croce L., Trentalance A., Augusti-Tocco G.: Characterization of the response of growth and differentiation to lipoproteins and agents affecting cholesterol metabolism in murine neuroblastoma cells. Int. J. Dev. Neurosci. 12:77-84, 1994.
13. Jakobisiak M., Bruno S., Skierski J.S., Darzynkiewicz Z.: Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. USA. 88:3628-3632, 1991.
14. Morris T.J., Palm S.L., Furcht L.L., Buchwald H.: Effect of Lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth. Ann. Surg. Oncol. 2:266-274, 1995.
15. Newman A., Clutterbuck R.D., Powles R.L., Millar J.L.: Selective inhibition of primary acute myeloid leukemia cell growth by lovastatin. Leukemia 8:274-280, 1994.
16. Prasanna P., Thibault A., Liu L., Samid D.: Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J. Neurochem. 66:710-716, 1996.
17. Sumi S., Beauchamp R.D., Townsend C.M. Jr., Pour P.M., Ishizuka J., Thompson J.C.: Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas 9:657-661, 1994.
18. Wedje J., Blegen H., Larsson O.: Requirements for mevalonate in the control of proliferation of human breast cancer cells. Anticancer Res. 12:317-324, 1992.
19. Matar P., Rozados V.R., Binda M.M., Roggero E.A., Bonfil R.D., Scharovsky O.G.: Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin. & Exp. Metastasis 17:19-25, 1999.
20. Matar P., Rozados V.R., Roggero E.A., Scharovsky O.G.: Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. Cancer Biother. & Radiopharm. 13:387-393, 1998.
21. Soma M.R., Baetta R., De Renzis M.R. et al.: In vivo enhanced antitumor activity of Carmustine [N,N′-Bis(2-chloroethy)-N-nitrosourea)] by Simvastatin. Cancer Res. 55:597-602, 1995.
22. Sumi S., Beauchamp R.D., Townsend C.M. Jr. et al.: Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 103:982-989, 1992.
23. Scharovsky O.G., Rozados V.R., Gervasoni S.I., Matar P.: Inhibition of ras oncogene: a novel approach to antineoplastic therapy. J. Biomed. Sci. 7:292-298, 2000.
24. Miller A.C., Kariko K., Myers C.E., Clark E.P., Samid D.: Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int. J. Cancer 53:302-307, 1993.
25. Miller A.C., Gafner J., Clark E.P., Samid D.: Differences in radiation-induced micronuclei yields of human cells: influence of ras gene expression and protein localization. Int. J. Radiat. Biol. 64:547-554, 1993.
26. 2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3beta (GSK-3beta) in vitro. Br. J. Cancer 88:1470-1479, 2003.
27. Keyomarsi K., Sandoval L., Band V., Pardee A.B.: Synchronization of tumor and normal cells from G1 to multiple cell cycles by Lovastatin. Cancer Res. 51:3602-3609, 1991.
28. Calderari S., Font M.T., Garrocq O. et al.: The inbred IIM/Fm stock. Rat News Lett. 25:28-29, 1991.
29. Canadian Council on American Care Guide to the Care and Use of Experimental Animals, Vol 1, 1993, 2° Ed.
30. Font M.T., Celoria G.C., Hinrichsen L.I.: Genetic analysis of tumor resistance in an inbred line of rats. Medicina (Buenos Aires) 43:502-508, 1983.
31. ICRU Report 35, ICRU, Washington DC, 1984:80-83.
32. Iliakis G., Wang Y., Guan J., Wang H.: DNA checkpoint control in cells exposed to ionizing radiation. Oncogene 22:5834-5847, 2003.
33. Fritz G., Brachetti C., Kaina B.: Lovastatin causes sensitization of HeLa cells to ionizing radiation-induced apoptosis by the abrogation of G2 blockage. Int. J. Radiat. Oncol. 79:601-610, 2003.
34. Larner J., Jane J., Laws E., Packer R., Myers C., Shaffrey M.A.: Phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am. J. Clin. Oncol. 21:579-583, 1998.
35. Michael J.M., Lavin M.F., Watters D.J.: Resistance to radiation-induced apoptosis in Burkitt's lymphoma cells is associated with defective ceramid signaling. Cancer Res. 57:3600-3605, 1997.
36. van Engeland M., Nieland L.J., Ramaekers F.C.S., Schutte B., Reutelingsperger C.P.M.: Annexin V-affinity assay. A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31:1-9, 1998.
37. Rozados V.R., Binda M.M., Matar P., Gervasoni S.I., Bonfil R.D., Scharovsky O.G.: Inhibition of p21ras membrane anchorage by Lovastatin treatment of a rat lymphoma. Biocell 24:171-171, 2000.
38. Kennedy S.G., Wagner A.J., Conzen S.D. et al.: The PI3K-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11:701-713, 1997.
39. Beaupre D.M., Kurzrock R.: RAS and Leukemia: From Basic Mechanisms to Gene-Directed Therapy. J. Clin. Oncol. 17:1071-1079, 1999.
40. Hernández-Alcoceba R., del Peso L., Lacal J.C.: The Ras family of GTPases in cancer cell invasion. Cell Mol. Life Sci. 57:65-765, 2000.
41. Crespo P., León J.: Ras proteins in the control of cell cycle and cell differentiation. Cell Mol. Life Sci. 57:1613-1636, 2000.